Sanofi has pioneered the development and delivery of transformative therapies for patients affected by debilitating diseases for over 30 years. We accomplish our goals through world-class research, collaboration with the global patient community, and with the compassion and commitment of our employees.
With a focus on rare diseases, multiple sclerosis and onco-immunology, we are dedicated to making a positive impact on the lives of the patients and families we serve. Sanofi's portfolio of transformative therapies, which are marketed in countries around the world, represent groundbreaking and life-saving advances in medicine. Sanofi employees benefit from the reach and resources of one of the world's largest pharmaceutical companies with a shared commitment to improving the lives of patients.
Sanofi’s Oncology franchise has a diverse and fast growing portfolio. This includes the late-stage launching candidates PD1-inhibitor (cemiplimab) in diverse tumors, anti-CD38 (isatuximab) in multiple myeloma, Amcenestrant in Breast Cancer, Tusamitamab in NSCLC as well as a growing number of early development programs in key tumor types. We are rapidly advancing a robust and reinvigorated oncology pipeline in different malignancies including lung, skin cancers, AML and GI tumors etc. Our marketed products span prostate, colorectal and hematological malignancies. This is an opportunity to be part of the team that brings cutting edge, innovative medications to the patients.
The Health Economics and Value Assessment (HEVA) business partner for breast cancer franchise in collaboration with the cross functional team will bring forward the value of our therapies to multiple stakeholders including patients
This role will be responsible for the design and execution of Health Economic and Outcomes Research (HEOR) research in the forms of economic modeling, database analysis, observational research, Clinical Outcomes Assessment (COA) development and validation, systematic literature review, evidence synthesis, value dossier development and other types of HEOR research to support global launch of a breast
This role will set the HEOR evidence generation priorities for each Oncology indication under development and incorporate them into broader Sanofi planning documents such as the integrated evidence generation plan (IEGP).
This role will operate as part of a multi-functional global development team that is responsible for designing clinical research programs to meet the evidentiary standards of regulators, health technology assessment (HTA) organizations, reimbursement authorities, third-party payers and other organizations that review evidence relevant to Sanofi medicines.
Advanced degree (PhD, MD, MS, MPH, or PharmD) in a scientific discipline
Minimum of 3 years of combined experience in health economics, outcomes research, or a related field
Demonstrated experience in applying various HEOR methods to specific research projects
Publications in peer-reviewed journals
Knowledge of global HTA processes and guidelines, experience with HTA submissions preferred
Strong ability to partner with colleagues from other (i.e. non-HEOR) functional areas
Proficiency in principles of evidence-based medicine and clinical research methodology
Skills & Competencies:
English fluent, both written and oral
Strong communication skills, both verbal and written, including presentation skills. Significant experience making presentations to senior management is strongly desired
Understanding of the legal and regulatory environment of the pharmaceutical industry, demonstrated integrity on work-related compliance considerations and solid ethics
Entrepreneurial and team spirit and ability to develop creative solutions to complex problems
ability to work in a matrix structure and cross functionally with countries, other Sanofi teams
The successful candidate will be required to sign and execute a restricted covenant upon hire.
As a healthcare company and a vaccine manufacturer, Sanofi has an important responsibility to protect individual and public health. All US based roles require individuals to be fully vaccinated against COVID-19 as part of your job responsibilities.
According to the CDC, an individual is considered to be “fully vaccinated” fourteen (14) days after receiving (a) the second dose of the Moderna or Pfizer vaccine, or (b) the single dose of the J&J vaccine. Fully vaccinated, for new Sanofi employees, is to be fully vaccinated 14 DAYS PRIOR TO START DATE.
Sanofi Inc. and its U.S. affiliates are Equal Opportunity and Affirmative Action employers committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status; domestic violence victim status; atypical cellular or blood trait; genetic information (including the refusal to submit to genetic testing) or any other characteristic protected by law.
At Sanofi diversity and inclusion is foundational to how we operate and embedded in our Core Values. We recognize to truly tap into the richness diversity brings we must lead with inclusion and have a workplace where those differences can thrive and be leveraged to empower the lives of our colleagues, patients and customers. We respect and celebrate the diversity of our people, their backgrounds and experiences and provide equal opportunity for all.